智通财经APP讯，派格生物医药-B(02565)发布公告，本公司已收到中国证监会就实施H股全流通而发出日期为2026年3月26日的备案通知书。根据备案通知书，本公司就合计1.02亿股未上市股份实施H股全流通向中国证监会作出的备案已经完成。倘自备案通知书日期起计12个月内未完成股份转换，且本公司仍有意进行该转换，则本公司应当向中国证监会更新备案材料。本公司将向联交所申请批准该等H股于联交所主板上市及买卖。
智通财经APP讯，派格生物医药-B(02565)发布公告，本公司已收到中国证监会就实施H股全流通而发出日期为2026年3月26日的备案通知书。根据备案通知书，本公司就合计1.02亿股未上市股份实施H股全流通向中国证监会作出的备案已经完成。倘自备案通知书日期起计12个月内未完成股份转换，且本公司仍有意进行该转换，则本公司应当向中国证监会更新备案材料。本公司将向联交所申请批准该等H股于联交所主板上市及买卖。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.